Hip Fracture

1
Pipeline Programs
3
Companies
2
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
1
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

1 companies ranked by most advanced pipeline stage

M&
Merck & Co.RAHWAY, NJ
2 programs
1
MK0677Phase 21 trial
Systematic Prevention of Further Fractures in Patients With Hip Fractures and Osteoporosis.N/A1 trial
Active Trials
NCT00414830Unknown600Est. Sep 2009
NCT00128115Terminated83Est. Aug 2007

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Merck & Co.MK0677
Merck & Co.Systematic Prevention of Further Fractures in Patients With Hip Fractures and Osteoporosis.

Clinical Trials (2)

Total enrollment: 683 patients across 2 trials

Treatment of Sarcopenia in Post-Hip Fracture Patients (0677-032)

Start: Sep 2005Est. completion: Aug 200783 patients
Phase 2Terminated
NCT00414830Merck & Co.Systematic Prevention of Further Fractures in Patients With Hip Fractures and Osteoporosis.

Systematic Prevention of Further Fractures in Patients With Hip Fractures and Osteoporosis.

Start: Jan 2005Est. completion: Sep 2009600 patients
N/AUnknown

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

3 companies competing in this space